Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The treatment of MRSA pneumonia is often regarded as problematic, with unacceptably high morbidity and mortality rates among affected patients. Two recent prospective, randomized, double-blind trials found that linezolid was non-inferior to vancomycin for the treatment of nosocomial pneumonia.

Linezolid for Nosocomial MRSA Pneumonia: A Better Option?